With inflation pressures, higher bond yields and energy costs in focus, many investors are looking for opportunities in smaller stocks that are not weighed down by weak balance sheets. That is where the Elite Penny Stocks screener comes in, filtering for companies that still have the cash strength to pursue their growth plans. Instead of trawling through hundreds of fragile penny stocks, you get a curated pool that starts with financial resilience. In this article, you will see 3 of the strongest stocks from that screener and how they fit into today’s macro backdrop.

Grab Holdings (GRAB)

Overview: Grab Holdings runs a superapp across Southeast Asia that brings together ride-hailing, food and package delivery, digital payments, and banking-style services for tens of millions of consumers and merchants. It aims to be everyday infrastructure in markets where smartphones are widespread but traditional banking and offline services are still catching up.

Operations: Grab generates most of its revenue from Deliveries at US$1.9b and Mobility at US$1.3b, with smaller contributions from Financial Services at US$379m and Other activities at US$4m.

Market Cap: US$14.9b

Grab stands out in the screener because it combines a sizeable superapp footprint with reported profitability in recent years and Q1 2026 net income of US$136m on revenue of US$955m. Analysts have published expectations for revenue and earnings, and one widely used fair value estimate based on future cash flows indicates a higher value than the current share price. At the same time, investors need to weigh thin margins, a relatively high reliance on external funding, and governance questions around a young board. For readers who want exposure to Southeast Asia’s digital economy, a key consideration is whether these risks are acceptable given the potential identified by more detailed analysis.

Grab’s reported profitability and superapp scale could be masking where the real upside and pressure points sit in the story, so review the 4 key rewards and 1 important major warning sign before the next twist becomes obvious.

Marqeta (MQ)

Overview: Marqeta runs a cloud based platform that helps companies issue debit, prepaid, credit, virtual, and physical cards, and handle the underlying payments processing, fraud controls, and account features that sit behind many modern fintech and embedded finance apps.

Operations: Marqeta generates US$651.6m in data processing revenue, with around US$551.2m from the United States and US$100.4m from markets outside the United States.

Market Cap: US$1.7b

Investors looking at the Elite Penny Stocks screener may find Marqeta interesting because it sits at the center of card issuing for fintechs, BNPL providers, and gig economy platforms, with product additions like AI powered risk scoring that aim to keep its services embedded in client offerings. Recent results showed GAAP net income of US$8m and 19% gross profit growth in Q1 2026, but profitability has been uneven, with a net loss of US$13.9m for 2025 and margins under pressure from one off items. Reliance on a few large customers, a relatively high P/S versus peers, and elevated external funding are key risks. The key consideration for investors is whether the potential upside from new products and expanding use cases compensates for that concentration and funding risk profile.

Marqeta’s role at the center of card issuing and embedded finance can make that 19% gross profit growth in Q1 2026 look like only part of the story, so review the analyst forecasts for Marqeta to see what the current customer concentration and funding mix might really be pointing to next.

Clover Health Investments (CLOV)

Overview: Clover Health Investments provides Medicare Advantage plans to eligible individuals in the United States and supports physicians with Clover Assistant, a software platform designed to help identify and manage chronic diseases more efficiently.

Operations: Clover Health generates US$2.2b in revenue from its Insurance segment, all of which currently comes from the United States.

Market Cap: US$1.7b

Clover Health may appeal to investors seeking exposure to Medicare Advantage and healthcare technology in one stock. It combines a 4 star PPO rating, which can lift reimbursement, with a data driven care model aimed at better medical margins. The company is still reporting losses, and analysts have published expectations for earnings and revenue, while recent updates highlight GAAP net income profitability in Q1 2026, strong 2025 revenue of US$1.9b, and growing membership. At the same time, heavy reliance on external funding, rising medical costs, regulatory shifts, and ongoing competition from larger insurers mean the path to profitability involves meaningful uncertainty, which is why the balance of risk and opportunity here may merit closer attention.

Clover Health’s mix of Medicare exposure, Q1 2026 GAAP net income profitability and a data driven care model could be masking the real tension in the story, so read the analyst forecasts for Clover Health Investments before the next inflection point becomes clearer

The 3 stocks you have just seen are only a sample. The full screener surfaces 24 more companies that share the same cash strength and potential for compelling growth stories as the ones already highlighted through the Elite Penny Stocks screener. Unlock the rest of the field and use Simply Wall St to filter by balance sheet resilience, funding runway, and specific catalysts so you can identify and analyze the highest conviction penny stock ideas for your watchlist.

Take Control of Your Investment Journey

If Marqeta or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Before They Fly?

Fresh stock ideas do not stay under the radar for long. Before momentum builds and ideal entry points start dropping away, scan these focused shortlists and consider getting in at an earlier stage.

• Spot undervalued quality by reviewing companies in the 44 high quality undervalued stocks while they are still under the radar for now, before sentiment and pricing potentially catch up.
• Focus on real business momentum by tracking the 60 profitable AI stocks that aren't just burning cash and concentrating on AI stocks already generating cash instead of those still burning through their runway.
• Target resilience with upside by screening the 69 resilient stocks with low risk scores so you are less likely to be caught chasing volatile ideas while steadier opportunities quietly build traction.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.